Internal Medicine, Hematology & Oncology · Flint, MI
NPI
1942243597
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
302 Kensington Ave
Flint, MI, 48503
Phone (810) 762-8200
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
97,172 services
Medicare patients, 2024
522
Average age 73
Drug cost, 2024
$6.5M
1,819 prescriptions
Company payments, 2025
$888
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher S Szyarto was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 43,350 times for 66 patients. In total Christopher S Szyarto billed 97,172 services in 104 codes, and Medicare paid $1.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-08-05.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 43,350 | 66 | $0.28 | $12K |
| J0897 Injection, denosumab, 1 mg | Office | 2,340 | 13 | $20.22 | $47K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 796 | 13 | $6.36 | $5,062 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 695 | 33 | $0.09 | $59.22 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 580 | 25 | $0.71 | $410 |
| 85025 Blood Count | Office | 379 | 167 | $7.61 | $2,884 |
| 99214 Office E&M - Established | Office | 327 | 134 | $88.88 | $29K |
| 99213 Office E&M - Established | Office | 263 | 179 | $58.66 | $15K |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 240 | 13 | $111.09 | $27K |
| 96372 Injection Administration | Office | 208 | 64 | $9.82 | $2,043 |
| 96413 Chemotherapy Administration | Office | 128 | 45 | $88.84 | $11K |
| 96367 Intravenous Infusion, Hydration | Office | 125 | 36 | $19.91 | $2,489 |
| J9045 Injection, carboplatin, 50 mg | Office | 123 | 11 | $2.81 | $346 |
| 96365 Intravenous Infusion, Hydration | Office | 122 | 76 | $44.78 | $5,463 |
| 96375 Injection Administration | Office | 116 | 36 | $10.81 | $1,254 |
By year: 2022 $1.1M for 70,221 services; 2023 $1.6M for 91,769 services; 2024 $1.3M for 97,172 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 379 | 167 | $7.61 | $2,884 |
Medicare prescription drug claims, 2024
In 2024, the drug Christopher S Szyarto prescribed most often to Medicare patients was Exemestane, with 170 prescriptions and refills. In total Christopher S Szyarto wrote 1,819 Medicare prescriptions that cost $6.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Exemestane Generic | 170 | 486 | 51 | $64K |
| Eliquis Apixaban | 73 | 149 | 21 | $81K |
| Oxycodone Hcl Generic | 72 | 72 | 23 | $1,434 |
| Lenalidomide Generic | 71 | 71 | Under 11 | $1.1M |
| Prochlorperazine Maleate Generic | 62 | 62 | 41 | $929 |
| Ondansetron Odt Ondansetron | 61 | 62 | 39 | $1,629 |
| Xarelto Rivaroxaban | 58 | 92 | 12 | $49K |
| Revlimid Lenalidomide | 58 | 58 | Under 11 | $1.5M |
| Tamoxifen Citrate Generic | 55 | 141 | 15 | $1,780 |
| Xtandi Enzalutamide | 55 | 55 | Under 11 | $734K |
| Allopurinol Generic | 49 | 103 | 13 | $578 |
| Hydroxyurea Generic | 44 | 71 | Under 11 | $821 |
| Gabapentin Generic | 42 | 48 | Under 11 | $602 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 42 | 42 | 26 | $394 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 42 | 42 | 29 | $918 |
Brand drugs: 463 claims; generic drugs: 1,356 claims; opioid claims: 175.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher S Szyarto $888 ($888 in general payments such as food, travel and fees) from 20 companies. The largest payer was Novartis Pharmaceuticals Corporation with $214.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 15 | $214 |
| Axsome Therapeutics, Inc. AXSM | 1 | $119 |
| Abbvie Inc. ABBV | 3 | $88.03 |
| Astellas Pharma US Inc 4503.T | 3 | $65.53 |
| Stemline Therapeutics Inc. | 3 | $63.87 |
| EMD Serono, Inc. MRK.DE | 2 | $41.63 |
| GlaxoSmithKline, LLC. GSK | 2 | $38.87 |
| Janssen Biotech, Inc. JNJ | 2 | $34.99 |
| SpringWorks Therapeutics, Inc. | 1 | $23.55 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $23.35 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.